
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.

TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.

The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.

FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.

The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.

Natera’s blood test analyzes cell-free DNA to screen for several cancer types from a single sample.

The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.

This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.

FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary–only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.

FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.

FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.

The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.

FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.

The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.

The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.

The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.

Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.

The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.

The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.

Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.